Home > Cardiology > ESC 2022 > AXIOMATIC-SSP: Reducing risk of ischaemic stroke with factor XIa inhibition?

AXIOMATIC-SSP: Reducing risk of ischaemic stroke with factor XIa inhibition?

Presented By
Dr Mukul Sharma, McMaster University, Canada
Conference
ESC 2022
Trial
Phase 2, AXIOMATIC-SSP
Late-breaking findings from the phase 2, dose-ranging AXIOMATIC-SSP trial showed that, although dose response was not observed, a 30% relative risk reduction was demonstrated in symptomatic ischaemic strokes for patients randomised to milvexian arms compared with placebo in participants treated with dual antiplatelets. The milvexian safety signal was also encouraging: no fatal bleeding and no increase in symptomatic intracranial haemorrhage was reported. Milvexian is a small molecule inhibitor that binds activated factor XI with high affinity and selectivity and may reduce the risk of stroke when added to antiplatelet drugs without significant bleeding. Because genetic variants known to reduce factor XI levels are associated with reduced risk for ischaemic stroke but are not associated with increased intracranial bleeding, the rationale behind the AXIOMATIC-SSP trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on